Efficacy and Safety of DWP450 for Treating Crows Feet Lines(CFL) in Combination With Glabellar Lines(Extension Study)
Launched by DAEWOONG PHARMACEUTICAL CO. LTD. · Jun 8, 2017
Trial Information
Current as of August 28, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Male or female of at least 18 to 75 years old
- • moderate-to-severe CFL at maximum smile on the FWS as rated by the investigator
- • moderate-to-severe GL at maximum frawn on the FWS as rated by the investigator
- • Subject who has completed phase 3 study for CFL.
About Daewoong Pharmaceutical Co. Ltd.
Daewoong Pharmaceutical Co., Ltd. is a leading South Korean biopharmaceutical company committed to advancing healthcare through innovative research and development. With a strong focus on the discovery and commercialization of novel therapeutics, Daewoong specializes in a diverse range of therapeutic areas, including gastroenterology, endocrinology, and neurology. The company is dedicated to improving patient outcomes by leveraging cutting-edge technology and scientific expertise, and it actively engages in global clinical trials to bring new treatments to market. Daewoong's commitment to quality and innovation positions it as a key player in the pharmaceutical industry, striving to enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials